Purdue Files ANDA Amid Global Bankruptcy Settlement Bid
Company Seeking To Become ‘Public Health Company’
Purdue Pharma has taken a step in its bid to develop and market generic versions of treatments to reverse opioid overdose “at or below cost,” following its filing for bankruptcy.
You may also be interested in...
As sponsors and US FDA continue to face fallout, newly launched digital archive of industry documents from opioid litigation and settlements will be free public resource for those investigating activities that led to the opioid epidemic. It is modeled on the archive of tobacco industry documents, which has been the basis of about 1,000 scientific publications.
Teva CEO Kåre Schultz has spoken at great length and in great detail about Teva’s ability to reach a proposed settlement in the US over allegations the firm helped fuel the opioid epidemic, revealing that a deal may be only 12 months away.
Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.